Compare Quest Diagnostics Inc (DGX) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs HubSpot Inc — how do they compare? Quest Diagnostics Inc trades at $205.37 (market cap $22.80B), while HubSpot Inc trades at $216.5 (market cap $10.73B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× HubSpot Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while HubSpot Inc pays none. Which is the better fit depends on your goals.
| DGX | HUBS | |
|---|---|---|
Market Cap | $22.80B | $10.73B |
Sector | Health | Technology |
52-Week High | $216.02 | $560.90 |
52-Week Low | $166.42 | $170.39 |
Enterprise Value | $28.82B | $9.29B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
HubSpot (HUBS) trades at $217.59, up 4.87% with a bullish technical signal. The stock shows strong revenue growth, reaching $3.13B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53. Recent news highlights AI-driven expansion and customer growth, with the company hosting an Analyst Day in September 2026.
The outlook for HUBS is favorable due to robust fundamentals and AI integration, but risks include high valuation multiples and competitive pressures. Upside potential exists if earnings growth continues, though investors should monitor margin expansion and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
